AI-Driven Drug Discovery Ushers in “China’s Moment”
Mar 28,2026
It seems that no one is now questioning whether AI-driven drug discovery is a bubble. There is now a broad consensus on the value of AI in pharmaceuticals.
Since the beginning of this year, both financing and IPO activity in China’s AI-driven drug discovery sector have accelerated, and partnerships with multinational pharmaceutical companies have become the norm. This not only reflects the current state of AI drug discovery but also underscores the remarkable momentum of indigenous innovation.
Innovation is shifting eastward—where does regulation stand?
Mar 27,2026
China is rapidly emerging as a major global hub for pharmaceutical R&D.
A set of compelling statistics illustrates this trend: between 2015 and 2024, the number of global drug-development projects nearly doubled, rising from approximately 10,400 to 19,000. During this period, the number of U.S.-based projects increased from about 5,000 to over 7,000, yet their share of the global total declined from 48% to 37%. In contrast, China’s share surged from 830 to more than 6,000 projects, making it the primary driver of global growth.
Multinational Pharmaceutical Companies Are “Increasing Their Positions” in China
Mar 25,2026
Multinational pharmaceutical companies are casting a vote of confidence—with real money—and that vote is squarely in favor of China.
At the recently held China Development Forum, leaders of participating multinational pharmaceutical firms unanimously stated that China occupies a pivotal position in the global pharmaceutical market and has become fully integrated into the global biopharmaceutical innovation ecosystem. They remain highly optimistic about the prospects for China’s pharmaceutical industry and are committed to increasing their investments, bringing more cutting-edge international products and technologies into China to support the development of “Healthy China.”
8 Billion in M&A Within Two Days: China’s Innovative Drugs Are Becoming Global “Hard Currency”
Mar 25,2026
A wave of mergers and acquisitions involving innovative Chinese drug assets is poised to surge once again.
On March 24, the Financial Times reported that pharmaceutical giant Merck is nearing a deal to acquire Terns Pharma in an all-cash transaction valued at approximately US$6 billion.
Just one day earlier, Gilead Sciences announced it would acquire Ouro Medicines, a NewCo company, for US$2.175 billion. The core asset of Ouro Medicines—a BCMA/CD3 bispecific T-cell engager antibody—originates from the Chinese biopharmaceutical firm Conua.
Chinese Pharmaceutical Companies “Challenge” the World’s Most Expensive
Mar 24,2026
In March 2026, the Two Sessions of the National People’s Congress and the Chinese People’s Political Consultative Conference officially designated biopharmaceuticals as an “emerging pillar industry,” placing it on par with integrated circuits and aerospace. This marks a historic elevation in the strategic status of the biopharmaceutical industry, upgrading it from an “emerging industry” to a core sector that underpins the national economy.
This transformation is particularly evident in the field of gene therapy. As one of the pharmaceutical industry’s most formidable strongholds, gene therapy is characterized by high technological barriers, a small patient population, and individual treatment costs often running into millions of dollars. For a time, industry insiders believed that such therapies exhibited “immune competition,” making them unattractive to latecomers.
The Inaugural CNS Innovative Drug R&D Conference Is Here | CPIC Global Conference
Mar 23,2026
As Chinese assets have become key partners for global pharmaceutical companies and as China’s innovative medicines have emerged as important “leaders” in the global pharmaceutical market, there is an urgent need to establish a regular, international, and market-oriented high-end conference platform within China—one that systematically showcases the strengths of China’s innovative drugs, facilitates connections between multinational pharmaceutical firms and overseas investment institutions, leads the formulation of global industry standards, and drives the upgrading of the innovation ecosystem.
Mar 22,2026
The inaugural Global Conference on Innovative Drugs of Major Countries, hosted by Tongxiyì, will be grandly held at the National Exhibition and Convention Center (Shanghai) from July 22 to 24, 2026.
This conference is benchmarked against the J.P. Morgan Healthcare Conference in the United States, establishing a new paradigm of “China’s Innovation—Global Translation—Shanghai Transactions.” It is not merely a showcase of cutting-edge technologies; rather, it is a strategic event aimed at solidifying the status of biopharmaceuticals as a national pillar industry and advancing China’s innovative drugs onto the global stage. The conference is committed to fostering deep synergy between innovation and finance, demonstrating China’s R&D efficiency, expanding the scope of global collaboration, and significantly enhancing the international influence of China’s new drugs.
Zhu Xun: It’s Time for China’s Innovative Drugs to Shift from “R&D Stories” to “Profit Stories”
Mar 21,2026
In less than 50 days, more than US$50 billion—when such a staggering figure emerged at the start of 2026, few could ignore the seismic wave that China’s innovative drugs have set off on the global stage. Going overseas is no longer a “nice-to-have” option as it was years ago; today, it has become an “essential” for Chinese biotech companies—and even a core benchmark for assessing their value.
Yet the more turbulent the tide, the more we need clear-sighted observers.
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
